EP4125865A4 - Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré - Google Patents

Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré Download PDF

Info

Publication number
EP4125865A4
EP4125865A4 EP21779685.3A EP21779685A EP4125865A4 EP 4125865 A4 EP4125865 A4 EP 4125865A4 EP 21779685 A EP21779685 A EP 21779685A EP 4125865 A4 EP4125865 A4 EP 4125865A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
related diseases
premature aging
treating age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21779685.3A
Other languages
German (de)
English (en)
Other versions
EP4125865A1 (fr
Inventor
Michael Friedrich ACKERMANN
Kelly J. ABERNATHY
Gregory Cooksey Rigdon
Stephen E. Butts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtsei Pharmaceuticals Inc
Original Assignee
Sirtsei Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtsei Pharmaceuticals Inc filed Critical Sirtsei Pharmaceuticals Inc
Publication of EP4125865A1 publication Critical patent/EP4125865A1/fr
Publication of EP4125865A4 publication Critical patent/EP4125865A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21779685.3A 2020-04-02 2021-04-01 Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré Pending EP4125865A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003977P 2020-04-02 2020-04-02
PCT/US2021/025295 WO2021202822A1 (fr) 2020-04-02 2021-04-01 Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré

Publications (2)

Publication Number Publication Date
EP4125865A1 EP4125865A1 (fr) 2023-02-08
EP4125865A4 true EP4125865A4 (fr) 2024-05-08

Family

ID=77930043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21779685.3A Pending EP4125865A4 (fr) 2020-04-02 2021-04-01 Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré

Country Status (5)

Country Link
US (1) US20230136792A1 (fr)
EP (1) EP4125865A4 (fr)
AU (1) AU2021247173A1 (fr)
CA (1) CA3168026A1 (fr)
WO (1) WO2021202822A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024026443A1 (fr) * 2022-07-28 2024-02-01 Sirtsei Pharmaceuticals, Inc. Compositions et méthodes pour améliorer la mémoire et la cognition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381203B2 (en) * 2013-03-15 2016-07-05 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124695A1 (fr) * 2009-04-26 2010-11-04 Soumia Goutali Utilisation de la griseofulvine dans l'amelioration des facultes mentales: attention, concentration et memoire
US9416143B2 (en) * 2012-08-01 2016-08-16 Pierre Fabre Medicament Griseofulvin derivatives
BR112018069712B1 (pt) * 2016-03-30 2024-01-02 Daiichi Sankyo Company, Limited Composto ou um sal farmacologicamente aceitável do mesmo, e composição farmacêutica
TWI811243B (zh) * 2017-09-29 2023-08-11 日商第一三共股份有限公司 灰黃黴素化合物及醫藥用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381203B2 (en) * 2013-03-15 2016-07-05 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1973, VANDAELE R: "Werner's syndrome: familial ulcerative scleroderma with cataract and diabetes", XP002811214, Database accession no. EMB-4168539 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 1992 (1992-05-01), ZATLOUKAL K ET AL: "Modulation of protein composition of nuclear lamina. Reduction of lamins B1 and B2 in livers of griseofulvin-treated mice.", XP002811213, Database accession no. NLM1573853 *
See also references of WO2021202822A1 *
SORRENTINO ET AL: "Anti-Inflammatory Properties of Griseofulvin", vol. 7, no. 1, 1 January 1977 (1977-01-01), pages 157 - 162, XP009514265, ISSN: 0065-4299, Retrieved from the Internet <URL:1077952576> DOI: 10.1007/BF01964914 *
VANDAELE R: "Werner's syndrome: familial ulcerative scleroderma with cataract and diabetes", ARCH.BELGES DERM. 1973, vol. 29, no. 3, 1973, pages 251 - 254 *
VIRENDRA N SEHGAL: "Antifungal Agents: Unapproved Uses, Dosages, or Indications Antiinflammatory Action of Griseofulvin", CLINICS IN DERMATOLOGY, 1 October 2002 (2002-10-01), pages 481 - 489, XP055609798, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0738081X0200278X/pdfft?md5=b16ec5973315aebc8c24df1324bd5122&pid=1-s2.0-S0738081X0200278X-main.pdf> [retrieved on 20190730] *
YUAN-SOON HO ET AL: "Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 91, no. 3, 14 December 2000 (2000-12-14), pages 393 - 401, XP071279978, ISSN: 0020-7136, DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1070>3.0.CO;2-# *
ZATLOUKAL K ET AL: "Modulation of protein composition of nuclear lamina. Reduction of lamins B1 and B2 in livers of griseofulvin-treated mice.", LABORATORY INVESTIGATION; A JOURNAL OF TECHNICAL METHODS AND PATHOLOGY MAY 1992, vol. 66, no. 5, May 1992 (1992-05-01), pages 589 - 597, ISSN: 0023-6837 *

Also Published As

Publication number Publication date
US20230136792A1 (en) 2023-05-04
AU2021247173A1 (en) 2022-09-29
WO2021202822A1 (fr) 2021-10-07
EP4125865A1 (fr) 2023-02-08
CA3168026A1 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
EP3920889A4 (fr) Exosomes contenant de la télomérase pour le traitement de maladies associées au vieillissement et à un dysfonctionnement d&#39;organe lié à l&#39;âge
EP4188368A4 (fr) Compositions et méthodes de traitement de maladies et de troubles
EP4157219A4 (fr) Méthodes et compositions permettant de traiter des maladies et des états de la rétine
EP4054713A4 (fr) Compositions et méthodes de traitement ou de prévention de maladies et de troubles cutanés au moyen de lekti
EP3914242A4 (fr) Compositions et méthodes pour le diagnostic et le traitement d&#39;affections liées à la longévité et à la qualité du vieillissement
EP4096439A4 (fr) Compositions et méthodes de traitement de troubles liés au vieillissement
EP4125865A4 (fr) Compositions et méthodes de traitement de maladies liées à l&#39;âge et de troubles du vieillissement prématuré
EP4208159A4 (fr) Compositions et méthodes de soulagement d&#39;affections et de troubles neurologiques
PT3861985T (pt) Composições e métodos para tratar doenças oculares
EP4097236A4 (fr) Compositions et méthodes pour traiter des maladies neurologiques
EP3955914A4 (fr) Nouveaux composés et méthodes d&#39;utilisation pour le traitement de troubles ou de maladies liés au fructose
EP3938364A4 (fr) Composés et méthodes de traitement de maladies
EP4175978A4 (fr) Compositions et méthodes pour traiter des maladies médiées par crp
EP4138779A4 (fr) Méthodes et compositions pour le traitement de la dégénérescence maculaire liée à l&#39;âge
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP4045084A4 (fr) Compositions et procédés pour traiter des troubles sanguins
EP4087847A4 (fr) Compositions et méthodes de traitement de maladies neurodégénératives
EP3993833A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP3986439A4 (fr) Compositions et méthodes utiles dans le traitement de maladies du cerveau
EP3917949A4 (fr) Compositions et procédés de traitement de maladies impliquant une fonction cxcl1
EP3917573A4 (fr) Procédés à base de crispr et nouvelles compositions pour le traitement de troubles vasculaires
EP4010020A4 (fr) Compositions et méthodes de traitement de maladies neurologiques
AU2021903256A0 (en) Compositions and methods for treating neurological disorders
AU2023903899A0 (en) Compositions and methods of treating gastrointestinal diseases and disorders
AU2022903123A0 (en) Compositions and methods for treating disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240328BHEP

Ipc: A61P 29/00 20060101ALI20240328BHEP

Ipc: A61P 27/00 20060101ALI20240328BHEP

Ipc: A61P 25/00 20060101ALI20240328BHEP

Ipc: A61P 17/00 20060101ALI20240328BHEP

Ipc: A61P 9/00 20060101ALI20240328BHEP

Ipc: C07D 307/94 20060101ALI20240328BHEP

Ipc: A61P 43/00 20060101ALI20240328BHEP

Ipc: A61K 31/343 20060101AFI20240328BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240409